Hormonal
Combining beinaglutide (0.2 mg TID) with metformin (850 mg BID) produces significantly greater weight loss and improvements in insulin sensitivity and hyperandrogenism compared to metformin monotherapy in obese women with PCOS over a 12-week period.
For obese women with PCOS who are already taking metformin but struggling with weight loss or high androgens, adding beinaglutide (starting low and titrating up) is a clinically superior strategy to staying on metformin alone. This combination leads to significantly more weight loss, better waist circumference reduction, and improved insulin sensitivity. While it involves injections, the study found that side effects were manageable and did not cause more people to quit than those taking metformin alone. This approach is particularly relevant for those who have not achieved sufficient results with lifestyle changes and metformin monotherapy.
Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC, WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events.
Why this rating
The study is a pilot randomized trial with a small sample size (n=60 completers) and short duration (12 weeks), limiting generalizability and long-term efficacy assessment.
Source
Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial
Qing Wen et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1156521
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →